retatrutide clinical trials sign up AllWell Clinical trial for chronic obesity

During the course of the study one subject from the control group dropped out, so that overall 79 subjects took part in the study

The peptide Bremelanotide PT 141 is now FDA approved to treat sexual dysfunction in women

It is used for primary carnitine deficiency and for metabolic conditions that lead to secondary carnitine deficiency

15% Patients lost an average of 15% of their body weight in ~1 year.* *In a 68-week double-blind trial studying once-weekly semaglutide injections (2.4 mg) in 1,961 patients without diabetes and with BMI 30, or BMI 27 with a weight-related condition, the average weight loss was 15%, when paired with diet and exercise changes

If daily pills have been problematic, weekly injection may improve your consistency